20 May 2025
9m
Stevenage, UK based TessellateBio recently signed a collaboration and licensing deal with Boehringer Ingelheim targeting tumors dependent on alternative lengthening of telomeres (ALT) for their growth
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.